Genotypic resistance to antiretroviral drugs in patients infected with several HIV type 1 genetic forms in Cuba

AIDS Research and Human Retroviruses

Volumn 23, Issue 3, 2007, Pages 407-414

  Pérez, Lissette ^a   Álvarez, Lucía Pérez ^b   Carmona, Rocío ^b   Aragonés, Carlos ^a   Delgado, Elena ^b   Thomson, Michael M ^b   González, Zoila ^a   Contreras, Gerardo ^b   Pérez, Jorge ^a   Nájera, Rafael ^b  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; CUBA; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BASE SEQUENCE; CROSS-SECTIONAL STUDIES; CUBA; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 34247185181     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0155     Document Type: Article

References (29)

1. Najera I, Richman DD, Olivares I, Rojas JM, Peinado MA, and Perucho M: Natural occurrence of drug resistance mutations in reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res Hum Reotrviruses 1994;10:1479-1488.
2. Najera I, Holguin A, Quiñones-Mateu ME, Muñoz-Fernandez MA, Najera R, Lopez-Galindez C, et al.: Pol gene quasispecies of human immunodeficiency virus: Mutations associated with drug resistance in virus from undergoing no drug therapy. J Virol 1995;69:23-31.
3. Lech W.J., Wang G, Yang YL, Chee Y, Dorman K, McCrae D, et al.: In vivo sequence diversity of the protease of human immunodeficiency, virus type 1: Presence of protease inhibitor-resistant variants in untreated subjects. J Virol 1996, 70:2038-2043.
4. Cannona R, Pérez Álvarez L, Muñoz M, Casado G, Delgado E, Sierra M, et al.: Natural resistance-associated mutations to enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients. J. Clin Virol 2005;32(3):248-253.
5. Soo-Yon R, Tommy Liu, Jaideep R, Matthew JG, and Shafer RW: Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing. Antimicrob Agents Chemother 2004;48(8),3122-3126.
6. Nájera R, Delgado E, Pérez-Álvarez L, and Thomson M: Genetic recombination and its role in the development of the HIV-1 pandemic. AIDS 2002;16(Suppl. 4):S3-16.
7. Rolo FM, Miranda L, Wainberg MA, Gu Z, Lobaina L, Noa E, et al.: Envelope V3 region sequences of Cuba HIV-1 isolates. J Acquir Immune Defic Syndr Hum Retroviral 1995;9(2):123-125.
8. Cuevas MT, Ruibal I, Villahermosa ML, Diaz H, Delgado E, Parga EV, et al.: High HIV-1 genetic diversity in Cuba. AIDS 2002;16(12):1643-1653.
9. Gomez CE, Inglesias E, Perdomo W, Rolo F, Blanco M, Lobaina L, et al.: Isolates from four different HIV-1 type 1 clades circulating in Cuba identified by DNA sequences of the C2-V3 region. AIDS Res Hum Retroviruses 2001;17(1):55-58.
10. Casado G, Thomson M, Sierra M, and Najera R: Identification of a novel HIV-1 circulating ADG intersubtype recombinant form (CRF19_cpx) in Cuba. J Acquir Immune Defic Syndr 2005;40(5): 532-537.
11. Thomson M, Casado G, Posada D, Sierra M, and Najera R: Identification of a novel HIV-1 complex circulating recombinant form (CRF18_cpx) of Central African origin in Cuba. AIDS 2005; 19(11):1155-1163.
12. Pérez L, Thomson M, Aragonés C, González Z, Pérez J, Casado G, et al.: Human immunodeficiency virus type 1 molecular epidemiology in Cuba: High genetic diversity, frequent mosaicism, and recent emergence of BG intersubtype recombinant forms. AIDS Res Hum Retroviruses 2006;22:724-733.
13. Ruibal-Brunet I, Cuevas MT, Diaz-Torres H, Villahermosa ML, Noa-Romero E, Vazquez de Parga E, et al.: Genotypic resistance mutations to antiretroviral drugs in HIV-1 B and non-B subtypes from Cuba. Pan Am Public Health 2001;10(3).
14. Villahermosa ML, Thomson M, Vazquez de Parga, et al.: Improved conditions for extraction and amplification of human immunodeficiency virus type 1 RNA from plasma samples with low viral load. J Hum Virol 2000;3:27-34.
15. Kumar S, Tamura K, and Nei M: MEGA3: Integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief Bioinform 2004;5:150-163.
16. Salminen MO, Carr JK, Burke DS, and McCutchan FE: Identification of breakpoints in intergenotypic recombinants of HIV type 1 by bootscanning. AIDS Res Hum Retroviruses 1995;11:1423-1425.
17. Loie KS, Bollinger RC, Paranjape RS, et al.: Full-length human immunodeficiency virus type 1 genomes from subtype C-infected Seroconverters in India, with evidence of intersubtype recombination. J Virol 1999;73:152-160.
18. Hillis DM and Bull JJ: An empirical test of bootstrapping as a method for assessing confidence in phylogenetic analysis. Syst Biol 1993;42:182-192.
19. Palalla F, Moorman A, Chmiel J, Chan C, and Holmberg S: Continued low morbidity and mortality among patients with advanced HIV infection and their patterns of HAART usage. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, 30 January-2 February 2000.
20. Palmer S, Alaeus A, Albert J, et al.: Drug susceptibily of subtypes A, B, C, D, and E human inmmunodeficiency virus type-1 primary isolates. AIDS Res Hum Retroviruses 1998;14:157-162.
21. Perez-Alvarez L, Cuevas MT, Villahermosa ML, Pedreira JD, Manjon N, Herrero I, et al.: Prevalence of drug resistance mutations in B, non-B subtypes, and recombinant forms of human immunodeficiency virus type 1 in infected individuals in Spain (Galicia). J Hum Virol 2001;4(1):35-38.
22. Kantor R and Katzenstein D: Drug resistance in non-subtype B HIV-1. J Clin Virol 2004;29(3):152-159.
23. Turner D, Brenner B, Moisi D, Detorio M, Cesaire R, Kurimura T, et al.: Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48(8):2993-2998.
24. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, et al.: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Med 2005;2(4):e112.
25. Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, et al.: A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS. 2003;17(1):F1-5.
26. Grossman Z, Istomin V, Averbuch D, Lorber M, Risenberg K, Levi I, et al.: Israel AIDS Multi-Center Study Group. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS. 2004;18(6):909-915.
27. Abecasis AB, Deforche K, Snoeck J, Bacheler LT, McKenna P, Carvalho AP, et al.: Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 2005;19(16):1799-1806.
28. Wensing AM, Van de Viiver DA, Angarano G, Asio B, Balotta C, et al.: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis 2005;192(6):958-966.
29. Vandamme AM, Sonnerborg A, Ait-Khaled M, et al.: Updated European recommendations for the clinical use of HIV drug resistance testing. Antiviral Ther 2004;9(6):829-848.